N/A N=511 A Multicenter, Open-Label, Non-Comparative Study of the Safety and Contraceptive Efficacy of the Woman's Condom
Contraception
Primary: 6 Month Pregnancy Probabilities With Typical Use — 0.5; 1.4; 4.0 percentage of probability
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=36 Influence of Antiretroviral Regimen on Immune Reconstitution in the Female Genital Tract
Women's Health · HIV Infection · Genital Diseases, Female
Primary: CD4+ to CD8+ T Cell Ratio in Cervical Biopsies — 0.46; 0.52 Cervical CD4+:CD8+ T cell ratio — p=0.6
Phase 1 N=64 Gardasil Vaccination in Post Stem Cell Transplant Patients
Gardasil Vaccine · Stem Cell Transplant · Immunogenicity
Primary: Percentage of Subjects Who Developed Antibody Response to the Vaccine. — 18; 20; 20 Participants
Phase 2 N=18 Evaluation of Reproducibility of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers
MALARIA · FEVER · Sweating Fever
Primary: Infection for P. Vivax — 11; 11; 9 days
Phase 1 N=36 A Single Dose Study About the Influence of Food on the Oral Bioavailability of Ladarixin Capsule in Healthy Volunteers
no Condition
Primary: Cmax of Plasma DF 2156Y — 67.345; 95.982 μg/mL — p=<0.0001
Phase 2 N=96 Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities
Healthy · Pituitary Disease · Thyroid Disease
Primary: TSH Response to TRH — 11.47 mcIU/mL
Phase 3 N=107 A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery
Intraoperative Ureter Visualization · Abdominolpelvic Surgery
Primary: Investigator Conspicuity Score Difference in Ureter Between WL and NIR-F at 30 Minutes [Adult (Normal/Mild): WL/NIR-F] — 2.7; 4.3 score on a scale — p=<0.001
Phase 1 N=88 Phase I, KM-819 in Healthy Subjects for Parkinson's Disease
Parkinson's Disease
Primary: Number of Participants With Adverse Events — 2; 2; 2; 1 participants
N/A N=523 Neuromuscular Intervention Targeted to Mechanisms of ACL Load in Female Athletes
ACL Injury
Primary: Number of Participants With Decrease in Knee Valgus Measurement — 307; 216 Participants
Phase 1 N=8 First-in-Human Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV367
Malaria,Falciparum
Primary: Number of Treatment-Emergent Adverse Events (TEAEs) — 1; 4; 5; 1 Number of events
Early Phase 1 N=6 VAC069: A Study of Blood-stage Controlled Human P. Vivax Infection
Malaria, Vivax
Primary: Number of Participants With Serious Adverse Events — 1 Participants
Phase 1 N=6 Clinical Trial to Study 4 Different Doses of the Vaccine RUTI in Healthy Volunteers
Latent Tuberculosis Infection · Tuberculosis
Primary: VAS Pain Score (Visual Analogic Scale, That Ranges From 0 to 100) to Evaluate Each Volunteer Subjective Pain Intensity at the Inoculation Point
N/A N=918 Expectation of Unpleasant Events in Anxiety Disorders
Anxiety Disorders
Primary: Change in Percent of Correct Button Presses During Threat Compared to the Safe Condition (AAST) — -0.016; 0.008 Percentage of accurate responses
Phase 3 N=126 Role of Magnesium Supplementation in the Treatment of Depression
Depression
Primary: Patient Health Questionnaire-9 — -4.28; -0.09 score on a scale
Phase 2 N=44 Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia
Primary: Number of Participants by Best Clinical Response Experienced — 20; 6; 6; 7 Participants